Phase I clinical trial with the AMC-bioartificial liver
Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF...
Gespeichert in:
| Veröffentlicht in: | International journal of artificial organs 2002-10, Vol.25 (10), p.950-959 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 959 |
|---|---|
| container_issue | 10 |
| container_start_page | 950 |
| container_title | International journal of artificial organs |
| container_volume | 25 |
| creator | van de Kerkhove, M P Di Florio, E Scuderi, V Mancini, A Belli, A Bracco, A Dauri, M Tisone, G Di Nicuolo, G Amoroso, P Spadari, A Lombardi, G Hoekstra, R Calise, F Chamuleau, R A F M |
| description | Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted.
Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft. |
| doi_str_mv | 10.1177/039139880202501009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72715274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19338175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-6f64ff8bd28cf882bb95f10446e27e244a0f7660a6d3338c14fb45bd965e7ea13</originalsourceid><addsrcrecordid>eNqFkDtPwzAUhS0EoqXwBxhQJrbAvX4mY1XxqFQEA8yR7diqUdoUOwHx70nUSgwMLPcM9zvfcAi5RLhBVOoWWImsLAqgQAUgQHlEpqgozyVwOCbTEchHYkLOUnoHQMm5OCUTpFxIYHJK1MtaJ5ctM9uEbbC6yboYhvsVunXWrV02f1rkJrQ6dsEHO76a8OniOTnxuknu4pAz8nZ_97p4zFfPD8vFfJVbxqDLpZfc-8LUtLC-KKgxpfAInEtHlaOca_BKStCyZowVFrk3XJi6lMIpp5HNyPXeu4vtR-9SV21Csq5p9Na1faoUVSio4v-CWA5-VGIA6R60sU0pOl_tYtjo-F0hVOOu1d9dh9LVwd6bjat_K4ch2Q8mcHB2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19338175</pqid></control><display><type>article</type><title>Phase I clinical trial with the AMC-bioartificial liver</title><source>MEDLINE</source><source>SAGE Complete</source><creator>van de Kerkhove, M P ; Di Florio, E ; Scuderi, V ; Mancini, A ; Belli, A ; Bracco, A ; Dauri, M ; Tisone, G ; Di Nicuolo, G ; Amoroso, P ; Spadari, A ; Lombardi, G ; Hoekstra, R ; Calise, F ; Chamuleau, R A F M</creator><creatorcontrib>van de Kerkhove, M P ; Di Florio, E ; Scuderi, V ; Mancini, A ; Belli, A ; Bracco, A ; Dauri, M ; Tisone, G ; Di Nicuolo, G ; Amoroso, P ; Spadari, A ; Lombardi, G ; Hoekstra, R ; Calise, F ; Chamuleau, R A F M</creatorcontrib><description>Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted.
Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.</description><identifier>ISSN: 0391-3988</identifier><identifier>EISSN: 1724-6040</identifier><identifier>DOI: 10.1177/039139880202501009</identifier><identifier>PMID: 12456036</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Extracorporeal Circulation ; Female ; Humans ; Liver Failure, Acute - therapy ; Liver Transplantation ; Liver, Artificial - adverse effects ; Male ; Middle Aged ; Waiting Lists</subject><ispartof>International journal of artificial organs, 2002-10, Vol.25 (10), p.950-959</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-6f64ff8bd28cf882bb95f10446e27e244a0f7660a6d3338c14fb45bd965e7ea13</citedby><cites>FETCH-LOGICAL-c330t-6f64ff8bd28cf882bb95f10446e27e244a0f7660a6d3338c14fb45bd965e7ea13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12456036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van de Kerkhove, M P</creatorcontrib><creatorcontrib>Di Florio, E</creatorcontrib><creatorcontrib>Scuderi, V</creatorcontrib><creatorcontrib>Mancini, A</creatorcontrib><creatorcontrib>Belli, A</creatorcontrib><creatorcontrib>Bracco, A</creatorcontrib><creatorcontrib>Dauri, M</creatorcontrib><creatorcontrib>Tisone, G</creatorcontrib><creatorcontrib>Di Nicuolo, G</creatorcontrib><creatorcontrib>Amoroso, P</creatorcontrib><creatorcontrib>Spadari, A</creatorcontrib><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Hoekstra, R</creatorcontrib><creatorcontrib>Calise, F</creatorcontrib><creatorcontrib>Chamuleau, R A F M</creatorcontrib><title>Phase I clinical trial with the AMC-bioartificial liver</title><title>International journal of artificial organs</title><addtitle>Int J Artif Organs</addtitle><description>Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted.
Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.</description><subject>Adult</subject><subject>Extracorporeal Circulation</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Failure, Acute - therapy</subject><subject>Liver Transplantation</subject><subject>Liver, Artificial - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Waiting Lists</subject><issn>0391-3988</issn><issn>1724-6040</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtPwzAUhS0EoqXwBxhQJrbAvX4mY1XxqFQEA8yR7diqUdoUOwHx70nUSgwMLPcM9zvfcAi5RLhBVOoWWImsLAqgQAUgQHlEpqgozyVwOCbTEchHYkLOUnoHQMm5OCUTpFxIYHJK1MtaJ5ctM9uEbbC6yboYhvsVunXWrV02f1rkJrQ6dsEHO76a8OniOTnxuknu4pAz8nZ_97p4zFfPD8vFfJVbxqDLpZfc-8LUtLC-KKgxpfAInEtHlaOca_BKStCyZowVFrk3XJi6lMIpp5HNyPXeu4vtR-9SV21Csq5p9Na1faoUVSio4v-CWA5-VGIA6R60sU0pOl_tYtjo-F0hVOOu1d9dh9LVwd6bjat_K4ch2Q8mcHB2</recordid><startdate>200210</startdate><enddate>200210</enddate><creator>van de Kerkhove, M P</creator><creator>Di Florio, E</creator><creator>Scuderi, V</creator><creator>Mancini, A</creator><creator>Belli, A</creator><creator>Bracco, A</creator><creator>Dauri, M</creator><creator>Tisone, G</creator><creator>Di Nicuolo, G</creator><creator>Amoroso, P</creator><creator>Spadari, A</creator><creator>Lombardi, G</creator><creator>Hoekstra, R</creator><creator>Calise, F</creator><creator>Chamuleau, R A F M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200210</creationdate><title>Phase I clinical trial with the AMC-bioartificial liver</title><author>van de Kerkhove, M P ; Di Florio, E ; Scuderi, V ; Mancini, A ; Belli, A ; Bracco, A ; Dauri, M ; Tisone, G ; Di Nicuolo, G ; Amoroso, P ; Spadari, A ; Lombardi, G ; Hoekstra, R ; Calise, F ; Chamuleau, R A F M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-6f64ff8bd28cf882bb95f10446e27e244a0f7660a6d3338c14fb45bd965e7ea13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Extracorporeal Circulation</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Failure, Acute - therapy</topic><topic>Liver Transplantation</topic><topic>Liver, Artificial - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Waiting Lists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van de Kerkhove, M P</creatorcontrib><creatorcontrib>Di Florio, E</creatorcontrib><creatorcontrib>Scuderi, V</creatorcontrib><creatorcontrib>Mancini, A</creatorcontrib><creatorcontrib>Belli, A</creatorcontrib><creatorcontrib>Bracco, A</creatorcontrib><creatorcontrib>Dauri, M</creatorcontrib><creatorcontrib>Tisone, G</creatorcontrib><creatorcontrib>Di Nicuolo, G</creatorcontrib><creatorcontrib>Amoroso, P</creatorcontrib><creatorcontrib>Spadari, A</creatorcontrib><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Hoekstra, R</creatorcontrib><creatorcontrib>Calise, F</creatorcontrib><creatorcontrib>Chamuleau, R A F M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of artificial organs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van de Kerkhove, M P</au><au>Di Florio, E</au><au>Scuderi, V</au><au>Mancini, A</au><au>Belli, A</au><au>Bracco, A</au><au>Dauri, M</au><au>Tisone, G</au><au>Di Nicuolo, G</au><au>Amoroso, P</au><au>Spadari, A</au><au>Lombardi, G</au><au>Hoekstra, R</au><au>Calise, F</au><au>Chamuleau, R A F M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I clinical trial with the AMC-bioartificial liver</atitle><jtitle>International journal of artificial organs</jtitle><addtitle>Int J Artif Organs</addtitle><date>2002-10</date><risdate>2002</risdate><volume>25</volume><issue>10</issue><spage>950</spage><epage>959</epage><pages>950-959</pages><issn>0391-3988</issn><eissn>1724-6040</eissn><abstract>Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted.
Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.</abstract><cop>United States</cop><pmid>12456036</pmid><doi>10.1177/039139880202501009</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0391-3988 |
| ispartof | International journal of artificial organs, 2002-10, Vol.25 (10), p.950-959 |
| issn | 0391-3988 1724-6040 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72715274 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Extracorporeal Circulation Female Humans Liver Failure, Acute - therapy Liver Transplantation Liver, Artificial - adverse effects Male Middle Aged Waiting Lists |
| title | Phase I clinical trial with the AMC-bioartificial liver |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A28%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20clinical%20trial%20with%20the%20AMC-bioartificial%20liver&rft.jtitle=International%20journal%20of%20artificial%20organs&rft.au=van%20de%20Kerkhove,%20M%20P&rft.date=2002-10&rft.volume=25&rft.issue=10&rft.spage=950&rft.epage=959&rft.pages=950-959&rft.issn=0391-3988&rft.eissn=1724-6040&rft_id=info:doi/10.1177/039139880202501009&rft_dat=%3Cproquest_cross%3E19338175%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19338175&rft_id=info:pmid/12456036&rfr_iscdi=true |